Integrated Filing — IndAS


General information about company

Scrip Code 544131
NSE Symbol GPTHEALTH
MSEI Symbol NOTLISTED
ISIN INE486R01017
Name of company GPT HEALTHCARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 23-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 23-May-2025   15:30:00
End date and time of board meeting 23-May-2025   16:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2023-09-27
Indicate Company website link for updated RPT policy of the Company https://ilshospitals.com/wp-content/uploads/2023/12/ghl-related_party_transactions_policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no such cases



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1014022000 4070914000
Other income 15729000 84943000
Total income 1029751000 4155857000
2 Expenses
(a) Cost of materials consumed 199537000 787934000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0 0
(d) Employee benefit expense 180553000 730154000
(e) Finance costs 10172000 34715000
(f) Depreciation, depletion and amortisation expense 48769000 190300000
(f) Other Expenses
1 Other Expenses 427031000 1719298000
Total other expenses 427031000 1719298000
Total expenses 866062000 3462401000
3 Total profit before exceptional items and tax 163689000 693456000
4 Exceptional items 0 0
5 Total profit before tax 163689000 693456000
6 Tax expense
7 Current tax 26689000 120889000
8 Deferred tax 8100000 73350000
9 Total tax expenses 34789000 194239000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 128900000 499217000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 128900000 499217000
17 Other comprehensive income net of taxes 1793000 -477000
18 Total Comprehensive Income for the period 130693000 498740000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 820548000 820548000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 1657958000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.57 6.08
Diluted earnings (loss) per share from continuing operations 1.57 6.08
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.57 6.08
Diluted earnings (loss) per share from continuing and discontinued operations 1.57 6.08
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2025598000
Capital work-in-progress 463303000
Investment property 0
Goodwill 0
Other intangible assets 9865000
Intangible assets under development 243348000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 1834000
Other non-current financial assets 164476000
Total non-current financial assets 166310000
Deferred tax assets (net) 0
Other non-current assets 145949000
Total non-current assets 3054373000
2 Current assets
Inventories 88250000
Current financial asset
Current investments 319803000
Trade receivables, current 249129000
Cash and cash equivalents 16588000
Bank balance other than cash and cash equivalents 26119000
Loans, current 1718000
Other current financial assets 63898000
Total current financial assets 677255000
Current tax assets (net) 0
Other current assets 22656000
Total current assets 788161000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3842534000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 820548000
Other equity 1657958000
Total equity attributable to owners of parent 2478506000
Non controlling interest
Total equity 2478506000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 55300000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 171954000
Total non-current financial liabilities 227254000
Provisions, non-current 94615000
Deferred tax liabilities (net) 192751000
Deferred government grants, Non-current
Other non-current liabilities 106976000
Total non-current liabilities 621596000
Current liabilities
Current financial liabilities
Borrowings, current 77689000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 8155000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 339447000
Total Trade payable 347602000
Other current financial liabilities 249801000
Total current financial liabilities 675092000
Other current liabilities 61401000
Provisions, current 5939000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 742432000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 1364028000
Total equity and liabilites 3842534000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plan 2530000 -673000
Total Amount of items that will not be reclassified to profit and loss 2530000 -673000
2 Income tax relating to items that will not be reclassified to profit or loss 737000 -196000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 1793000 -477000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 693456000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 34715000
Adjustments for decrease (increase) in inventories -6701000
Adjustments for decrease (increase) in trade receivables, current -1444000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 0
Adjustments for decrease (increase) in other non-current assets -6977000
Adjustments for other financial assets, non-current -6394000
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -23834000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities -8803000
Adjustments for depreciation and amortisation expense 190300000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 12871000
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 5189000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 48753000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 11145000
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 151314000
Net cash flows from (used in) operations 844770000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 170809000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 673961000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 4886000
Purchase of property, plant and equipment 499256000
Proceeds from sales of investment property 136512000
Purchase of investment property 148823000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 49794000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 130970000
Net cash flows from (used in) investing activities -325917000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 96137000
Repayments of borrowings 87548000
Payments of lease liabilities 53915000
Dividends paid 287192000
Interest paid 15870000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -348388000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -344000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -344000
Cash and cash equivalents cash flow statement at beginning of period 16932000
Cash and cash equivalents cash flow statement at end of period 16588000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S.R. Batliboi & Co. LLP Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 GPT HEALTHCARE LIMITED GPT ESTATE PRIVATE LIMITED Directors of this Company are relatives of Chairman, Managing Director, Director and Executive Director Any other transaction Payment of lease liabilities 10620000 approval has been obtained 10620000 2209000 1246000
2 GPT HEALTHCARE LIMITED GPT ESTATE PRIVATE LIMITED Directors of this Company are relatives of Chairman, Managing Director, Director and Executive Director Any other transaction Security deposit paid 0 approval has been obtained 0 97000000 97000000
3 GPT HEALTHCARE LIMITED Mr. Dwarika Prasad Tantia Executive Chairman of the Company Remuneration 23184000 approval has been obtained 23184000 3620000 8197000
4 GPT HEALTHCARE LIMITED Dr Om Tantia Managing Director of the Company Remuneration 14229000 approval has been obtained 14229000 3884000 2711000
5 GPT HEALTHCARE LIMITED Mr. Anurag Tantia Executive Director of the Company Remuneration 9231000 approval has been obtained 9231000 2051000 1916000
6 GPT HEALTHCARE LIMITED Mrs. Kriti Tantia Relative of Chairman and CFO of the Company Remuneration 6225000 approval has been obtained 6225000 1670000 1547000
7 GPT HEALTHCARE LIMITED Mr. Ankur Sharma Company Secretary & Compliance Officer of the Company Remuneration 655000 approval has been obtained 655000 80000 167000
8 GPT HEALTHCARE LIMITED Dr. Aruna Tantia Director of the Company Any other transaction Doctor Payout 2208000 approval has been obtained 2208000 432000 90000
9 GPT HEALTHCARE LIMITED Dr. Ghanshyam Goyal Director of the Company Any other transaction Doctor Payout 7600000 approval has been obtained 7600000 1360000 1421000
10 GPT HEALTHCARE LIMITED Dr. Ankush Bansal Relative of Dr Ghanshyam Goyal, Director of the Company Any other transaction Doctor Payout 757000 approval has been obtained 757000 93000 223000
11 GPT HEALTHCARE LIMITED Dr. Nandita Bansal Relative of Dr Ghanshyam Goyal, Director of the Company Any other transaction Doctor Payout 11000 approval has been obtained 11000 0 0
12 GPT HEALTHCARE LIMITED GPT Sons Private Limited Holding Company Dividend paid 0 Not applicable 53804000 0 0
13 GPT HEALTHCARE LIMITED Dr. Aruna Tantia Director of the Company Dividend paid 0 Not applicable 0 0 0
14 GPT HEALTHCARE LIMITED Mr. Kashi Prasad Khandelwal Independent Director of the Company Any other transaction Director sitting fees 272000 Not applicable 272000 0 0
15 GPT HEALTHCARE LIMITED Mr. Hari Modi Independent Director of the Company Any other transaction Director sitting fees 149000 Not applicable 149000 0 0
16 GPT HEALTHCARE LIMITED Dr. Tapti Sen Independent Director of the Company Any other transaction Director sitting fees 218000 Not applicable 218000 0 0
17 GPT HEALTHCARE LIMITED Mr. Deepak Pramanik Independent Director of the Company Any other transaction Director sitting fees 265000 Not applicable 265000 0 0
18 GPT HEALTHCARE LIMITED Mr. Dwarika Prasad Tantia Executive Chairman of the Company Dividend paid 0 Not applicable 0 0 0
19 GPT HEALTHCARE LIMITED Mrs Pramila Tantia Relative of the Executive Chairman of the Company Dividend paid 0 Not applicable 0 0 0
20 GPT HEALTHCARE LIMITED Dr. Om Tantia Managing Director of the Company Dividend paid 0 Not applicable 0 0 0
21 GPT HEALTHCARE LIMITED Amrendra Prasad Verma Independent Director of the Company Any other transaction Director sitting fees 265000 Not applicable 265000 0 0
22 GPT HEALTHCARE LIMITED Govardhan Foundation A Charitable Trust in which Chairman, Managing Director and relative are trustee Any other transaction CSR Expenses 4850000 approval has been obtained 4850000 2596000 0
23 GPT HEALTHCARE LIMITED GPT Healthcare Education Trust Entities in which KMP exercises significant influences Any other transaction Other Income 600000 approval has been obtained 600000 0 98000
24 GPT HEALTHCARE LIMITED Dr. Aruna Tantia Director of the Company Any other transaction Director sitting fees 116000 approval has been obtained 116000 0 0
25 GPT HEALTHCARE LIMITED Dr. Ghanshyam Goyal Director of the Company Any other transaction Director sitting fees 62000 approval has been obtained 62000 0 0
Total value of transaction during the reporting period 135321000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt